GMAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Genmab A/S is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has supportive analyst coverage and a catalyst-rich pipeline, but the current price action is weak, the latest quarter showed sharply lower earnings despite revenue growth, and there is no strong proprietary buy signal today. My direct view: hold off for now rather than buying immediately.
GMAB is in a short-term bearish setup. The pre-market price is 26.28, down 0.90%, with price below the pivot at 27.234 and close to first support at 26.031. MACD histogram is negative at -0.177 and still below zero, while the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). RSI_6 at 38.244 is neutral-to-weak, not oversold enough to strongly improve the entry case. The near-term pattern bias also points lower, with a 60% chance of declines over the next day, week, and month based on similar candlestick behavior.
Goldman highlighted a 'catalyst-rich' 2026, with potential value from Epkinly, Rina-S, and petosemtamab. Wells Fargo also sees 2026 as an inflection year with key readouts, and Jefferies believes acquisitions reduce terminal value risk. Revenue growth in the latest quarter was solid at 14.63% YoY, showing the business still has top-line momentum.
No news catalysts appeared in the last week, so there is no fresh event-driven momentum today. Earnings quality was weak in the latest quarter: net income fell 94.38% YoY and EPS dropped 94.26% YoY, even though revenue rose. Gross margin also slipped to 92.34%. Technically the stock is under pressure with bearish moving averages and negative MACD. Hedge funds and insiders are neutral, and there is no congress trading support. The Darzalex royalty expiration risk in 2029 remains a longer-term overhang noted by analysts.
Latest reported quarter: 2025/Q4. Revenue increased to 1.058B, up 14.63% YoY, which is a positive growth sign. But profitability deteriorated sharply, with net income down 94.38% YoY to 31M and EPS down 94.26% YoY to 0.49. Gross margin also declined by 2.59% YoY to 92.34. This is a mixed quarter: strong sales growth, but much weaker bottom-line performance.
Recent analyst trend is mostly positive. H.C. Wainwright kept a Buy but trimmed its target to $38 from $40. BNP Paribas upgraded to Outperform with a DKK 2,400 target. Goldman Sachs upgraded to Buy with a $30.50 target, calling 2026 catalyst-rich. Wolfe and Wells Fargo both initiated with Outperform/Overweight and targets of $32 and $40, respectively. Guggenheim and Jefferies also stayed bullish, while Morgan Stanley remained more cautious at Equal Weight with a $34 target. Overall Wall Street is constructive, but the range of targets suggests upside exists mainly if clinical catalysts deliver.
